FDA: J&J’s Ditropan Labeling Should Be Strengthened To Advise Of Hallucinations
This article was originally published in The Pink Sheet Daily
Executive Summary
Documents issued ahead of a Pediatric Advisory Committee meeting April 11 urge stronger caution due to CNS effects of oxybutynin.